HG
BDTX icon

Herbst Group’s Black Diamond Therapeutics BDTX Stock Holding History

Herbst Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,635
Closed -$38.3K – 64
2023
Q4 		$38.3K Hold
13,635
– – 0.02% 61
2023
Q3 		$39.1K Hold
13,635
– – 0.03% 70
2023
Q2 		$68.9K Buy
+13,635
New +$27.8K 0.05% 70

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Herbst Group's BDTX Position: Q1 2024 in Review

Herbst Group sold out of Black Diamond Therapeutics (BDTX) in Q1 2024, closing a stake of 13,635 shares — an estimated $38.3K sold.

Herbst Group first reported a position in BDTX in Q2 2023 and held it in 3 quarters. The position peaked at $68.9K in Q2 2023. 88 funds tracked by Wall St. Rank hold BDTX as of Q1 2024.

  • Herbst Group reported no remaining Black Diamond Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Herbst Group sold 13,635 Black Diamond Therapeutics shares in Q1 2024, an estimated $38.3K.
  • Herbst Group first reported a position in Black Diamond Therapeutics in Q2 2023 and held it in 3 quarters.
  • Herbst Group's Black Diamond Therapeutics position peaked at $68.9K in Q2 2023.
  • 88 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2024.

Based on Herbst Group's 13F filing for Q1 2024, filed 22 Apr 2024.